Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Today, Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a biopharmaceutical company with a market capitalization of $713 million and impressive revenue growth of ~30% over the last twelve months, conducted its 2025 Annual Meeting of Stockholders. According to an 8-K filing with the Securities and Exchange Commission, the meeting was held with a quorum of 111,098,912 shares represented by proxy out of 156,384,578 outstanding shares.
The primary agenda included the election of three Class I directors. BJ Bormann, James Brady, and Garheng Kong were elected to serve until the 2028 Annual Meeting. Bormann received 57,050,196 votes in favor and 21,676,213 votes withheld. Brady secured 76,465,887 votes in favor, with 2,260,522 votes withheld. Kong garnered 75,938,627 votes in favor and 2,787,782 votes withheld. Each nominee was elected by a plurality vote as per the company’s bylaws. InvestingPro analysis shows the company maintains a GOOD financial health score, with particularly strong performance metrics over the past year.
Additionally, the stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The vote concluded with 110,053,757 in favor, 744,492 against, and 300,663 abstentions.
The meeting also included a non-binding advisory vote on executive compensation. The proposal to approve the compensation of named executive officers passed with 72,202,176 votes in favor, 5,633,615 against, and 890,618 abstentions.
This information is based on a press release statement filed with the SEC. The company’s stock has delivered an exceptional 91% return over the past year, trading at $4.43, and according to InvestingPro analysis, appears slightly undervalued based on its Fair Value estimate. Subscribers can access additional ProTips and comprehensive financial metrics through the platform’s detailed research reports.
In other recent news, Xeris Biopharma Holdings, Inc. reported a 48% increase in first-quarter 2025 revenue, reaching $60.1 million, surpassing the forecasted $57.88 million. Despite this strong revenue performance, the company posted an earnings per share (EPS) of -$0.06, slightly missing the forecast of -$0.05. Key products such as RECORLEV and Gvoke contributed significantly to the revenue growth, with RECORLEV revenue up 141% to $25.5 million. The company also raised its full-year revenue guidance to between $255 million and $260 million, reflecting confidence in its future performance. During its first Analyst and Investor Day, Xeris outlined ambitious financial projections, including a 2025 revenue target of $260 to $275 million and a long-term goal of $1 billion in annual net revenues for Recorlev by 2035. The company emphasized its financial strength, aiming to maintain positive adjusted EBITDA status. Analysts are keeping a close watch on Xeris, as firms like Piper Sandler and Leerink Partners have shown interest in the company’s strategic plans and product developments. Additionally, Xeris is advancing its pipeline with products like XP-8121, targeting hypothyroidism, which could further bolster its market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.